Novartis Pharmaceuticals Corp. beat back a challenge to its blockbuster multiple sclerosis drug Gilenya in a Delaware federal court ruling unsealed on Monday, with the judge finding Novartis’ patent valid and holding that a planned generic by HEC Pharm infringed…

Read this piece in its entirety at Law360.